Stoke Therapeutics Inc. (STOK) — closed signal from January 27, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 27, 2026.
Predicted vs. what happened
What happened
Reached its target in 27 days.
The thesis — published January 27, 2026
Stoke is a risky stock that could bounce in the next 0-3 months after recent big price swings. The company gave new timing for a late-stage drug study and will present at a major healthcare conference, which can bring new attention. Because trading is thin, buy small and wait for clear price improvement before increasing size; sudden big moves are possible.
Primary drivers
- New clinical timing can change what investors expect
- Conference presentation can attract fresh investor interest
- Price could rebound after recent large swings
- Biotech events can give uneven but big upside
How it played out
STOK: target reached in 27 days
Lyra published STOK at $29.85 on January 27, 2026, with 20% expected growth over a short-term window ending April 27, 2026. The thesis pointed to new timing for a late-stage drug study, a healthcare conference presentation, a possible rebound after large price swings, and uneven but large upside around biotech events.
Inside the window, STOK reached the $35.81 target in 27 days. It later peaked at $40.22 on March 10, 2026, for a 34.8% gain. By the window close, it ended at $33.71. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.